Connect with us

NEWS

A Breakthrough in Psychiatric Care: Antipsychotics Mitigate Marijuana-Induced Psychosis

Published

on

Recent studies have shed light on the effectiveness of antipsychotic medications in treating episodes of psychosis induced by marijuana overuse. This discovery offers hope for improved management of psychiatric conditions associated with cannabis use disorder.

Marijuana-induced psychosis, a concerning consequence of excessive cannabis use, manifests as a disconnection from reality, often necessitating hospitalization. Research led by Dr. Alexander Denissoff from the University of Turku in Finland has revealed that early intervention with second-generation, long-acting injectable antipsychotics can significantly reduce hospitalization rates for patients experiencing their first psychotic episode due to marijuana overuse.

The study tracked 1,820 individuals who had a first psychotic episode and were diagnosed with cannabis use disorder between 2006 and 2021. Findings indicated that those who received antipsychotic medication were one-third less likely to need hospitalization for a psychotic relapse compared to those who did not receive these drugs.

The Role of Antipsychotics in Treatment

Antipsychotics, particularly risperidone, have shown promise in reducing the likelihood of hospitalization due to psychotic relapse by 60%, followed closely by aripiprazole, oral clozapine, and paliperidone. These medications appear to be crucial in preventing recurrent psychotic episodes, especially if individuals continue to use marijuana or fail to adhere to their prescribed treatment regimen.

For patients hospitalized due to substance use disorder, clozapine was the most effective, reducing the risk of re-hospitalization by 86%, with risperidone and paliperidone also demonstrating significant efficacy. These findings underscore the importance of timely and appropriate use of antipsychotics in managing marijuana-induced psychosis.

Implications for Future Treatment Strategies

The study’s insights are pivotal for developing secondary prevention strategies to manage cannabis use disorder and its psychiatric complications. By highlighting the benefits of specific antipsychotic medications, healthcare providers can better tailor treatments to prevent hospitalizations and improve patient outcomes.

Harry is the editor of TIMES OF CANNABIS, the independent cannabis news title he owns and runs, reporting on cannabis and hemp law, licensing, business and science. His journalism career spans ten years, from reporter to editor, and most of it has been spent following the legal cannabis industry as it grew. The stories start with documents: state and national statutes, the rules published by licensing agencies, court rulings, company filings and earnings, hemp testing standards and the studies behind claims about health effects. Sales totals, tax receipts and licence counts are checked against the original agency data before publication, and a figure that cannot be traced to a source does not run. A public corrections policy sets out how mistakes are handled, and corrected articles carry a note saying what changed. Coverage of medical use is reporting, not advice; the legal status of cannabis varies by jurisdiction, and anyone considering it for a health condition should speak with a clinician. Harry reads and answers mail at support@timesofcannabis.com.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending